Antibodies to carbonic anhydrase in patients with immune cholangiopathies

Gordon, Stuart C.; Quattrociocchi-Longe, Therese M.; Khan, Bilal Ahmad; Kodali, Valli P.; Chen, Jenn; Silverman, Ann L.; Kiechle, Frederick L.

doi:10.1016/0016-5085(95)90143-4

Cited by 97 publications

(42 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3][4][5][6] of serum non-organ-specific autoantibodies other than It has been reported that such patients tested positive for AMA. To evaluate if such a peculiar serum immunoreacother serum autoantibodies more frequently than AMA-positivity is associated with clinically relevant characteristive patients.…”

Section: 2 Negative Primary Biliary Cirrhosis (Pbc) Is a Distinctmentioning

confidence: 99%

“…To evaluate if such a peculiar serum immunoreacother serum autoantibodies more frequently than AMA-positivity is associated with clinically relevant characteristive patients. [3][4][5][6][7][8][9] Interestingly, in a small series of patients, a tics, we reviewed our experience with 297 Italian paconsistent association has been reported between the prestients who have had a clinical and histological diagnosis ence of antibodies against human carbonic anhydrase II and of PBC and were regularly followed-up at our Center AMA-negative PBC. 6 Terms as ''immunocholangitis'', 3 ''autofrom June 1974 to June 1994.…”

Section: 2 Negative Primary Biliary Cirrhosis (Pbc) Is a Distinctmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis

et al. 1997

View full text Add to dashboard Cite

Reports from North America and Northern Europe have suggested that antimitochondrial antibody (AMA) negative primary biliary cirrhosis (PBC) is a distinct chronic cholestatic liver disease with high prevalence of serum non‐organ‐specific autoantibodies other than AMA. To evaluate if such a peculiar serum immunoreactivity is associated with clinically relevant characteristics, we reviewed our experience with 297 Italian patients who have had a clinical and histological diagnosis of PBC and were regularly followed‐up at our Center from June 1974 to June 1994. AMA‐negative and AMA‐positive patients were compared in terms of biochemical and clinical features, and clinical outcome of the disease. At presentation, 30 of 297 patients (10%) tested negative for AMA by indirect immunofluorescence. Six of them tested positive for antimitochondrial M2 antibodies (AMA‐M2) by immunoblotting analysis, therefore, diagnosis of AMA‐negative PBC was made in 24 patients (8%). At the initial visit, AMA‐negative and AMA‐positive patients were similar in terms of biochemical and clinical features. Antinuclear and anti‐smooth‐muscle antibodies (ANA and ASMA) were more frequently positive in the AMA‐negative patients (71% vs. 31%, and 37% vs. 9%; both P = .0002). Incidence of complications of cirrhosis and development of liver failure resulting in death or referral for liver transplantation did not differ significantly between the two populations. In conclusion, data from this historical cohort study suggest that the distinct serological features of AMA‐negative PBC are not associated with substantial differences in the clinical spectrum or course of the disease.

show abstract

Section: 2 Negative Primary Biliary Cirrhosis (Pbc) Is a Distinctmentioning

confidence: 99%

Section: 2 Negative Primary Biliary Cirrhosis (Pbc) Is a Distinctmentioning

confidence: 99%

Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Serum HCV-RNA levels ranged from 1.5 1 types and/or hepatitis C viremia levels with demographic, 10 4 to 1.0 1 10 8 copies/mL with no significant differences biochemical, or histological characteristics of chronically inbetween median serum HCV-RNA concentrations in pa-fected patients are conflicting. [15][16][17][18][19][20][21][22][23][24][25][26] These issues are further tients infected with different genotypes/subtypes. Al-complicated by recent evaluations showing that common gethough patients infected with HCV-1b were older, no notyping methods lack specificity 12,27 and that quantification biochemical or histological evidence was obtained that systems underestimate high viremia levels 28 or specific HCV this subtype is associated with more severe liver disease.…”

mentioning

confidence: 99%

“…[20][21][22][23] In pa-types/subtypes, viremia, liver function test results, and histients with chronic persistent hepatitis, a significantly tology, respectively. These findings do not preclude the smaller amount of HCV-RNA was found than in those with association of certain HCV subtypes with a poorer response chronic active hepatitis or cirrhosis.…”

mentioning

confidence: 99%

Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histolog

et al. 1996

View full text Add to dashboard Cite

Nucleotide sequence analysis of hepatitis C virusHepatitis C virus (HCV) infection often progresses to (HCV) strains showed substantial variability leading to chronic hepatitis, cirrhosis, and possibly hepatocellular carcia classification into several genotypes and subtypes. The noma. [1][2][3] Using phylogenetic analysis of the viral 5-noncoding data correlating HCV genotypes and subtypes with hep-region, a classification of HCV strains into six major types atitis C viremia levels, demographic characteristics of (HCV-1 to -6) has been introduced. Analysis of the more varipatients (age, mode of transmission, duration of infec-able coding regions of the viral genome (core, envelope, nontion), and severity of liver disease are conflicting. The structural [NS]-3, and NS-5) indicated that major genotypes interpretation of several studies is further complicated are composed of two or more distinct subtypes, termed 1a, because the molecular methods used lacked specificity 1b, 2a etc. 4,5 The geographic distribution of HCV genomes for genotyping/subtyping and underestimated viremia differs considerably. In Europe and the United States, sublevels, especially in patients infected with HCV geno-types HCV-1a and -1b, HCV-2a and -2b, and HCV-3a are types 2 and 3. In the present study we investigated 97 most abundant, whereas in Japan HCV subtypes 1a and 3a consecutive patients with chronic hepatitis C using mo-are virtually nonexistent. Type 4 genotypes are common in lecular ''gold standard'' methods. HCV subtyping was patients from Northern Africa and the Middle East, and types performed by sequence and phylogenetic analysis of the 5 and 6 have been identified in serum samples obtained from nonstructural (NS)-5 region and serum HCV-RNA con-South Africa and Hong Kong, respectively. Sequence analysis centration was assessed by a validated genotype-inde-of HCV isolates from Vietnamese blood donors revealed addipendent quantitative reverse-transcription-polymerase tional major genetic groups (HCV-7, -8, and -9).6-8 chain reaction assay using an internal RNA standard.Several 9-12 but not all studies 13,14 have indicated a correlaPatients infected with subtypes HCV-1b, HCV-2a-c, and tion between HCV genotypes/subtypes and serum HCV-RNA HCV-4 were older than patients infected with HCV-1a concentrations. The data associating HCV genotypes/suband HCV-3a. Serum HCV-RNA levels ranged from 1.5 1 types and/or hepatitis C viremia levels with demographic, 10 4 to 1.0 1 10 8 copies/mL with no significant differences biochemical, or histological characteristics of chronically inbetween median serum HCV-RNA concentrations in pa-fected patients are conflicting. [15][16][17][18][19][20][21][22][23][24][25][26] These issues are further tients infected with different genotypes/subtypes. Al-complicated by recent evaluations showing that common gethough patients infected with HCV-1b were older, no notyping methods lack specificity 12,27 and that quantification biochemical or histological evidence was obtained that systems underestimate high virem...

show abstract

“…Anti-CA I and anti-CA II antibodies (aCAIab and aCAIIab) have recently been isolated from patients with systemic lupus erythematosus (8,9 ), polymyositis and systemic sclerosis (9 ), endometriosis (10,11 ), Sjö gren syndrome (8,9,12,13 ), idiopathic chronic pancreatitis (13,14 ), primary biliary cirrhosis (PBC) (12,13,15,16 ), and autoimmune cholangitis (15 ).…”

mentioning

confidence: 99%